Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF (tumor necrosis factor) drug adalimumab into Dupuytren’s disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren’s disease – potentially improving quality of life for patients not yet considered candidates for surgery.
Source: MedicalXpress
(NOTICE: This treatment has not yet been approved for use and is currently not offered at Dr. Jafarnia’s office.)
Read More
Comments are closed.